Idiopathic hemi-facial lipoatrophy treated with autologous fat transfer.

J Cosmet Dermatol

Department of Dermatology & Cutaneous Surgery, University of South Florida College of Medicine, Tampa, FL, USA.

Published: September 2010

Facial lipoatrophy can be socially disfiguring, often prompting patients to seek correction. A variety of agents are used to treat facial lipoatrophy, but the quest for the ideal agent remains elusive. We present a case of non-HIV associated, idiopathic hemi-facial lipoatrophy successfully treated with autologous fat transfer (ATF). Because ATF has no complications from antigenicity, it is a safe and cost-effective treatment option for patients with non-HIV associated cases of facial lipoatrophy and abundant donor tissue.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1473-2165.2010.00507.xDOI Listing

Publication Analysis

Top Keywords

facial lipoatrophy
12
idiopathic hemi-facial
8
hemi-facial lipoatrophy
8
lipoatrophy treated
8
treated autologous
8
autologous fat
8
fat transfer
8
non-hiv associated
8
lipoatrophy
5
transfer facial
4

Similar Publications

Ptosis in human immunodeficiency virus-infected patients under long-term antiretroviral treatment.

Clin Neurol Neurosurg

December 2024

Department of Neurosciences and Mental Health, Unidade Local de Saúde de Santa Maria, Lisbon, Portugal; Faculdade de Medicina-Instituto de Medicina Molecular, Centro de Estudos Egas Moniz, Universidade de Lisboa, Lisbon, Portugal.

Objective: To present cases of ptosis in HIV-1 patients on long-term antiretroviral therapy (ART) and review the existing literature.

Methods: Five HIV-1-positive patients with slowly progressive bilateral ptosis underwent a comprehensive diagnostic evaluation, including imaging studies, neurophysiological testing, muscle biopsy, and genetic analysis. A literature review was conducted.

View Article and Find Full Text PDF

Case Report: Concurrent pathogenic variants in the gene as a cause of sporadic partial lipodystrophy.

Front Genet

November 2024

Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

Introduction: Inherited lipodystrophies are a group of rare diseases defined by severe reduction in adipose tissue mass and classified as generalized or partial. We report a non-familial (sporadic) case of partial lipodystrophy caused by a novel genetic mechanism involving closely linked pathogenic variants in the gene.

Methods: A female adult with partial lipodystrophy and her parents were evaluated for gene variants across the exome under different mendelian inheritance models (autosomal dominant, recessive, compound heterozygous, and X-linked) to find pathogenic variants.

View Article and Find Full Text PDF

Current status and perspectives in the treatment of facial lipoatrophy in HIV-positive patients in 2024.

Ann Chir Plast Esthet

December 2024

Service de chirurgie plastique, réparatrice, esthétique, hôpital Cavale-Blanche, Brest, France.

Facial lipoatrophy, a sign of normal aging, also occurs due to lipodystrophy from metabolic disorders affecting lipogenesis. It can be hereditary or acquired, localized or generalized. In HIV patients, prolonged antiretroviral therapy (ART) is a major cause, affecting around 55% of patients with 47% experiencing facial lipoatrophy.

View Article and Find Full Text PDF
Article Synopsis
  • Lupus panniculitis is a chronic form of cutaneous lupus that causes painful, firm nodules on areas like the legs, face, and trunk, potentially leading to scarring or loss of fat in those areas.
  • Patients suffering from lipoatrophy due to lupus panniculitis may experience distress, and there is varying information on treating it with fat transfer or fillers.
  • A case study highlights a 37-year-old woman who successfully restored volume in her right cheek using injectable hyaluronic acid filler after experiencing lipoatrophy following a period of stable disease.
View Article and Find Full Text PDF

Treatment of facial lipodystrophy induced by a biologic agent (IPD-1): a literature review.

Einstein (Sao Paulo)

December 2024

Division of Plastic Surgery, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Agents that inhibit programmed cell death (IPD-1) in T lymphocytes are indicated for patients with advanced cancer. However, some individuals may develop endocrinological conditions, such as diabetes, thyroid dysfunction, and lipodystrophy, after treatment. This systematic review and case report of IPD-1 lipodystrophies describes a patient who received nivolumab treatment for advanced clear cell renal carcinoma and subsequently developed diabetes as well as facial and body lipodystrophy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!